Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study-Reference-Cited by-同舟云学术

Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study

Published:2019-11-13 Issue:3 Volume:267 Page:694-702
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Prosperini Luca^ORCID,Cortese Antonio,Lucchini Matteo,Boffa Laura,Borriello Giovanna,Buscarinu Maria Chiara,Capone Fioravante,Centonze Diego,De Fino Chiara,De Pascalis Daniela,Fantozzi Roberta,Ferraro Elisabetta,Filippi Maria,Galgani Simonetta,Gasperini Claudio,Haggiag Shalom,Landi Doriana,Marfia Girolama,Mataluni Giorgia,Millefiorini Enrico,Mirabella Massimiliano,Monteleone Fabrizia,Nociti Viviana,Pontecorvo Simona,Romano Silvia,Ruggieri Serena,Salvetti Marco,Tortorella Carla,Zannino Silvana,Di Battista Giancarlo

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-019-09625-1.pdf

Reference40 articles.

1. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O (2018) Multiple sclerosis. Lancet 391:1622–1636

2. Sabaté E (2003) Adherence to long-term therapies: evidence for action. WHO, Geneva

3. Rieckmann P, Boyko A, Centonze D et al (2015) Achieving patient engagement in multiple sclerosis: a perspective from the multiple sclerosis in the 21st century steering group. Mult Scler Relat Disord 4:202–218

4. Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L (2007) Adherence to interferon-β treatment and results of therapy switching. J Neurol Sci 259:104–108

5. McKay KA, Tremlett H, Patten SB, CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis et al (2017) Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: a cross-Canada prospective study. Mult Scler 23:588–596

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sclerosi multipla: trattamenti di base;EMC - Neurologia;2024-08

2. Dimethyl Fumarate or Teriflunomide for Relapsing–Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies;Neurotherapeutics;2023-09

3. Dimethyl fumarate or teriflunomide for relapsing-remitting multiple sclerosis: a meta-analysis of post-marketing studies;2023-06-24

4. Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing–remitting multiple sclerosis in Austria;Journal of Neurology;2023-03-02

5. Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide;Pharmaceuticals;2022-10-11